Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of hyperlipidemia
3.2.1.2 Advancements in drug development
3.2.1.3 Growing incidence of cardiovascular diseases
3.2.1.4 Rising geriatric population
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of advanced therapies
3.2.2.2 Side effects and adverse reactions
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
3.6.1 By region
3.6.2 By key player
3.7 Future market trends
3.8 Pipeline analysis
3.9 Porter’s analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Familial
5.3 Acquired
Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Statins
6.3 Bile acid sequestrants
6.4 Cholesterol absorption inhibitors
6.5 Fibric acid derivatives
6.6 PCSK9 inhibitors
6.7 Combination
6.8 Other drug classes
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AstraZeneca PLC
10.2 Amgen Inc.
10.3 Alnylam Pharmaceuticals, Inc.
10.4 Bristol-Myers Squibb Company
10.5 Dr. Reddy’s Laboratories Limited
10.6 Eli Lilly And Company
10.7 F. Hoffmann-La Roche Ltd
10.8 GSK plc
10.9 Johnson & Johnson
10.10 Merck & Co., Inc.
10.11 Novartis AG
10.12 Pfizer Inc.
10.13 Regeneron Pharmaceuticals, Inc.
10.14 Teva Pharmaceuticals Industries Ltd.
10.15 Sanofi
10.16 Sun Pharmaceutical Industries Ltd.
